Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

AMD

This page shows the latest AMD news and features for those working in and with pharma, biotech and healthcare.

Gyroscope advances gene therapy platform, merges with Orbit

Gyroscope advances gene therapy platform, merges with Orbit

approved therapies for the more common dry form of AMD. ... commercially”. He adds: “This marks an important step in fulfilling founding academics, David Kavanagh and Andrew Lotery’s vision of widespread use of genetically defined treatments for

Latest news

  • Novartis and Syncona back new Swiss biotech Anaveon Novartis and Syncona back new Swiss biotech Anaveon

    These include  Freeline, which last year raised £88m to accelerate haemophilia gene therapy, and Gyroscope, which earlier this month dosed its first patient with its gene therapy for dry AMD, and

  • Gyroscope's gene therapy given to first dry AMD patient Gyroscope's gene therapy given to first dry AMD patient

    Dry AMD is caused by the gradual death of retinal cells that can occur over many months or years and is far more common. ... We believe this is a great step forward in developing a therapy to treat dry AMD, while we continue our efforts on expanding our

  • Alector kicks off next wave of biotech IPOs Alector kicks off next wave of biotech IPOs

    In December the Boston-based company gained a valuable FDA fast track designation for its lead candidate, elamipretide, a treatment for dry age-related macular degeneration (AMD), for which there are

  • Bayer to challenge Avastin legal ruling Bayer to challenge Avastin legal ruling

    age-related macular degeneration (wet AMD) in place of two licensed but much more expensive treatments, Bayer’s Eylea and Novartis’ Lucentis. ... The NHS in England spends around £500m on licensed wet AMD treatments every year, with around £300m

  • After Lucentis setback, Novartis trumpets data on follow-up drug After Lucentis setback, Novartis trumpets data on follow-up drug

    of Lucentis and Eylea for AMD, even though Avastin isn’t approved for the indication. ... Meanwhile, Eylea has been gaining ground in wet AMD thanks to less frequent dosing, accord to GlobalData.

More from news
Approximately 24 fully matching, plus 69 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2018

    RNA‐targeted therapeutic, IONIS‐FB‐LRx targeting Factor. B, for Geographic Atrophy, an advanced form of dry Age-related Macular Degeneration (AMD). ... Effectively the deal is structured as an option, as the phase 2 study in dry AMD will be

  • 30 Women Leaders in UK Healthcare (part 2) 30 Women Leaders in UK Healthcare (part 2)

    treatments for age-related macular degeneration (AMD).

  • The good, the bad and the ugly The good, the bad and the ugly

    In the EU, where there’s a high prevalence of AMD, Bayer has enjoyed great success with Eylea - growing revenues by 18% in 2017,” says Alice Stevens, analyst, cardiovascular and metabolic ... The company plans to launch the highly anticipated

  • Working with our healthcare system more closely is vital Working with our healthcare system more closely is vital

    to essential treatment, expanding and improving care for people living with a leading cause of vision loss – age-related macular degeneration (AMD).

  • Deal Watch November 2015 Deal Watch November 2015

    The acquisition brings an ophthalmology focus with products for Stargardt's macular degeneration, dry AMD, and myopic macular degeneration. ... 380. Ocata Therapeutics. Astellas Pharma| Laurel. Acquisition - company. Regenerative medicine pipeline focus

More from intelligence
Approximately 0 fully matching, plus 11 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Quick links

Infographics

Multimedia